Does colchicine prevent heart failure post-MI in patients with elevated neutrophil MMA contents?
Neutrophil methylmalonic acid (MMA) is identified as a novel immunometabolic trigger for adverse cardiac remodeling post-MI, highlighting colchicine as a potential targeted therapy.
Neutrophil-derived MMA promotes NETosis and microthrombus formation through IL-6 activation, contributing to maladaptive cardiac remodeling post-MI. These findings identify neutrophil MMA as a novel immunometabolic trigger driving NET-mediated adverse cardiac remodeling and suggest colchicine as a promising therapeutic strategy to prevent heart failure post-MI, particularly in patients with elevated neutrophil MMA contents.
Liu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: